HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luis Paz-Ares Selected Research

Breast Neoplasms (Breast Cancer)

11/2022Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
12/2019Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.
1/2019Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
1/2018Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
8/2013Inhibition of HSP90 molecular chaperones: moving into the clinic.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Luis Paz-Ares Research Topics

Disease

132Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2024 - 12/2004
122Neoplasms (Cancer)
04/2024 - 05/2002
52Lung Neoplasms (Lung Cancer)
04/2024 - 06/2007
46Disease Progression
01/2024 - 04/2005
21Neutropenia
04/2024 - 05/2002
20Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/2024 - 06/2007
18Neoplasm Metastasis (Metastasis)
12/2023 - 08/2002
12Adenocarcinoma
08/2023 - 05/2013
12Carcinoma (Carcinomatosis)
01/2023 - 08/2002
11Adenocarcinoma of Lung
09/2023 - 06/2014
11Exanthema (Rash)
01/2017 - 12/2004
9Febrile Neutropenia
12/2023 - 06/2004
8Colorectal Neoplasms (Colorectal Cancer)
05/2024 - 05/2007
7Thrombocytopenia (Thrombopenia)
12/2023 - 04/2012
7Body Weight (Weight, Body)
08/2023 - 07/2015
7Fatigue
01/2023 - 03/2012
6Pneumonia (Pneumonitis)
11/2022 - 11/2017
5Anemia
04/2024 - 03/2013
5Carcinogenesis
08/2023 - 01/2015
5Breast Neoplasms (Breast Cancer)
11/2022 - 08/2013
5Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 05/2013
4Diarrhea
04/2024 - 01/2008
4Brain Neoplasms (Brain Tumor)
12/2023 - 01/2017
4Chest Pain (Chest Pains)
12/2023 - 01/2020
4Dyspnea (Shortness of Breath)
12/2023 - 01/2020
4Melanoma (Melanoma, Malignant)
08/2023 - 03/2009
4Asthenia
01/2021 - 01/2008
4Sarcoma (Soft Tissue Sarcoma)
01/2020 - 04/2012
4Nausea
01/2019 - 11/2014
3Leukopenia
04/2024 - 01/2019
3Thyroid Neoplasms (Thyroid Cancer)
11/2023 - 02/2010
3Ovarian Neoplasms (Ovarian Cancer)
01/2023 - 02/2015
3Interstitial Lung Diseases (Interstitial Lung Disease)
11/2022 - 01/2019
3Cough
10/2021 - 01/2020
3Fever (Fevers)
12/2019 - 05/2002
3Stomatitis
01/2019 - 11/2014
3Chronic Obstructive Pulmonary Disease (COPD)
12/2016 - 02/2013
3Acne Vulgaris
01/2016 - 01/2011
3Pathologic Processes
09/2014 - 01/2012

Drug/Important Bio-Agent (IBA)

51Biomarkers (Surrogate Marker)IBA
04/2024 - 01/2011
41PlatinumIBA
04/2024 - 01/2005
27ErbB Receptors (EGF Receptor)IBA
12/2023 - 06/2007
24Cisplatin (Platino)FDA LinkGeneric
10/2023 - 08/2002
24Proteins (Proteins, Gene)FDA Link
09/2023 - 06/2010
18Tyrosine Kinase InhibitorsIBA
12/2023 - 01/2008
17pembrolizumabIBA
04/2024 - 11/2018
17Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2023 - 06/2007
15NivolumabIBA
02/2024 - 07/2015
15Carboplatin (JM8)FDA LinkGeneric
10/2023 - 12/2004
14Pemetrexed (MTA)FDA Link
02/2024 - 12/2002
14durvalumabIBA
10/2023 - 11/2017
13Messenger RNA (mRNA)IBA
04/2024 - 07/2007
12B7-H1 AntigenIBA
01/2024 - 08/2017
12Immune Checkpoint InhibitorsIBA
12/2023 - 06/2015
11LigandsIBA
04/2024 - 10/2015
9Docetaxel (Taxotere)FDA Link
01/2024 - 07/2007
9Paclitaxel (Taxol)FDA LinkGeneric
10/2023 - 08/2002
8Phosphotransferases (Kinase)IBA
06/2023 - 06/2010
8RamucirumabIBA
01/2023 - 01/2017
7IpilimumabIBA
02/2024 - 05/2018
7PM 01183IBA
12/2023 - 01/2017
7Etoposide (VP 16)FDA LinkGeneric
10/2023 - 11/2017
7MicroRNAs (MicroRNA)IBA
02/2023 - 01/2012
7AfatinibIBA
01/2022 - 01/2016
7necitumumabIBA
03/2019 - 03/2015
7GemcitabineFDA Link
01/2017 - 08/2002
6Alanine Transaminase (SGPT)IBA
01/2020 - 05/2007
6Gefitinib (Iressa)FDA Link
01/2020 - 09/2009
5Irinotecan (Camptosar)FDA LinkGeneric
04/2024 - 05/2005
5Cetuximab (Erbitux)FDA Link
12/2023 - 01/2011
5Anaplastic Lymphoma KinaseIBA
07/2023 - 05/2012
5Transaminases (Aminotransferases)IBA
11/2022 - 05/2007
5Monoclonal AntibodiesIBA
06/2022 - 08/2017
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2020 - 06/2010
4Topotecan (Hycamtin)FDA LinkGeneric
04/2024 - 01/2019
4DNA (Deoxyribonucleic Acid)IBA
01/2023 - 05/2015
4AntibodiesIBA
10/2022 - 01/2014
4CytokinesIBA
03/2021 - 01/2016
3canakinumabFDA Link
01/2024 - 10/2023
3Heat-Shock Proteins (Heat-Shock Protein)IBA
09/2023 - 01/2019
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2023 - 01/2019
3abemaciclibIBA
11/2022 - 01/2016
3EnzymesIBA
03/2021 - 01/2016
3Cadherins (E-Cadherin)IBA
03/2021 - 01/2018
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2020 - 05/2007
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2019 - 04/2013
3TrabectedinIBA
09/2012 - 05/2007
3Fluorouracil (Carac)FDA LinkGeneric
01/2008 - 05/2005
2atezolizumabIBA
05/2024 - 08/2017
2sotorasibIBA
01/2024 - 01/2023
2InterleukinsIBA
12/2023 - 10/2023

Therapy/Procedure

78Therapeutics
04/2024 - 07/2007
77Drug Therapy (Chemotherapy)
04/2024 - 05/2002
16Immunotherapy
04/2024 - 07/2015
7Chemoradiotherapy
12/2022 - 12/2005
5Radiotherapy
06/2022 - 06/2007
4Precision Medicine
01/2023 - 01/2017
3Adjuvant Chemotherapy
10/2022 - 01/2017
3Aftercare (After-Treatment)
01/2020 - 10/2016
3TP protocol
04/2012 - 08/2002